EVOK - Evoke Pharma Inc. (EVOK) Q4 2023 Earnings Call Transcript
2024-03-14 21:33:12 ET
Evoke Pharma, Inc. (EVOK)
Q4 2023 Results Conference Call
March 14, 2024 04:30 PM ET
Company Participants
Daniel Kontoh-Boateng - Investor Relations
David Gonyer - Co-Founder, CEO & Director
Christopher Quesenberry - GIMOTI’s Chief Commercial Officer, EVERSANA
Matthew D'Onofrio - Chief Business Officer
Conference Call Participants
Yale Jen - Laidlaw & Company
Presentation
Operator
Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full-Year 2023 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode. [Operator Instructions] Please be advised that today’s call is being recorded.
I will now turn the call over to Daniel Kontoh-Boateng. Please go ahead, sir.
Daniel Kontoh-Boateng
Good afternoon, and thank you for participating in Evoke Pharma's conference call and webcast today. With me today are Dave Gonyer, Evoke's Chief Executive Officer; Chris Quesenberry, GIMOTI's Chief Commercial Officer from Eversana; and Matt D'Onofrio, Evoke's President and Chief Operating Officer.
By now, you should have a copy of the press release we issued earlier. If not, it is available on the Investor Relations page of our website at evokepharma.com. We encourage everyone to read today's press release as well as Evoke’s annual report on Form 10-K, which is now filed with the SEC. The company's Form 10-K and earnings release are also available on Evoke's website.
Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that, during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
These forward-looking statements are qualified by the cautionary statements contained in Evoke's press releases and SEC filings, including its annual report on Form 10-K and subsequent filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Evoke undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast....
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript